Skip to main content
. 2024 Dec 5;14:1491100. doi: 10.3389/fonc.2024.1491100

Figure 1.

Figure 1

Treatment and response of three DLBCL patients with HBV-related cirrhosis. R-CHOP, rituximab + cyclophosphamide + vindesine + adriamycin + dexamethasone regimen; CAR-T, chimeric antigen receptor T cell; BTKi, Bruton’s tyrosine kinase inhibitor; ASCT, autologous stem cell transplantation; RT, radiotherapy; CR, complete remission; PR, partial remission; SD, stable disease; PD, progressive disease.